This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Tobacco  • Drug Therapy, Other  • Alert me on articles by topic

No More Excuses to Delay Treatment

Arch Intern Med. 2006;166:1547-1550.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Smoking is the leading cause of preventable death in the United States and worldwide.¹ In the 20th century, smoking caused 100 million deaths. If present patterns persist, about 1 billion people will die from smoking-related diseases in this century. Finding efficacious treatments for nicotine dependence is an important health goal.²

Nicotine replacement therapy (NRT) is the mainstay of smoking cessation treatment. It includes chewing gum, skin patches, tablets, nasal spray, and inhalers and is designed to decrease withdrawal symptoms by replacing nicotine in the blood. All forms of NRT increase the likelihood that individuals will succeed in their smoking cessation attempts. The various types of NRT are equally efficacious, and additional counseling does not improve an individual's likelihood of success.³

Nevertheless, 3 major issues have promulgated scientific interest in the development of non-NRT pharmacotherapies for the treatment of nicotine dependence. First, although various forms of NRT can nearly double the . . . [Full Text of this Article]

AUTHOR INFORMATION
Bankole A. Johnson, DSc, MD, PhD

RELATED ARTICLES

Cytisine for Smoking Cessation: A Literature Review and a Meta-analysis
Jean-François Etter
Arch Intern Med. 2006;166(15):1553-1559.
ABSTRACT | FULL TEXT  

Smoking Cessation With Varenicline, a Selective 42 Nicotinic Receptor Partial Agonist: Results From a 7-Week, Randomized, Placebo- and Bupropion-Controlled Trial With 1-Year Follow-up
Mitchell Nides, Cheryl Oncken, David Gonzales, Stephen Rennard, Eric J. Watsky, Rich Anziano, Karen R. Reeves, and for the Varenicline Study Group
Arch Intern Med. 2006;166(15):1561-1568.
ABSTRACT | FULL TEXT  

Efficacy and Safety of the Novel Selective Nicotinic Acetylcholine Receptor Partial Agonist, Varenicline, for Smoking Cessation
Cheryl Oncken, David Gonzales, Mitchell Nides, Stephen Rennard, Eric Watsky, Clare B. Billing, Richard Anziano, Karen Reeves, and for the Varenicline Study Group
Arch Intern Med. 2006;166(15):1571-1577.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Another Arrow in the Quiver to Combat Smoking
Journal Watch Cardiology 2006;2006:4-4.
FULL TEXT